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Abstract: Viral diseases remain serious threats to public health because of the shortage of effective
means of control. To combat the surge of viral diseases, new treatments are urgently needed. Here
we show that small-molecules, which inhibit cellular anti-apoptotic Bcl-2 proteins (Bcl-2i), induced
the premature death of cells infected with different RNA or DNA viruses, whereas, at the same
concentrations, no toxicity was observed in mock-infected cells. Moreover, these compounds limited
viral replication and spread. Surprisingly, Bcl-2i also induced the premature apoptosis of cells
transfected with viral RNA or plasmid DNA but not of mock-transfected cells. These results suggest
that Bcl-2i sensitizes cells containing foreign RNA or DNA to apoptosis. A comparison of the toxicity,
antiviral activity, and side effects of six Bcl-2i allowed us to select A-1155463 as an antiviral lead
candidate. Thus, our results pave the way for the further development of Bcl-2i for the prevention
and treatment of viral diseases.
Keywords: apoptosis; antiviral agent; innate immunity; host response
1. Introduction
Globalization, environmental changes, population growth, and urbanization make viral diseases
(VDs) one of the major causes of morbidity and mortality in the world [1,2]. In particular, emerging
and re-emerging VDs pose a constant threat to public health [3]. To date, 90 antiviral drugs have
been approved to treat human immunodeficiency virus (HIV) 1 and 2, hepatitis B and C viruses (HBV
and HCV), cytomegalovirus (CMV), herpes simplex virus (HSV) 1 and 2, human papilloma virus
(HPV), varicella zoster virus (VZV), vaccinia virus (VACV), Epstein-Barr virus (EBV), respiratory
syncytial virus (RSV), or influenza A and B virus (IAV and FLUBV) infections but not other important
VDs [4]. Only aciclovir (HSV-1/-2, VZV), famiciclovir (HSV-1/-2, VZV), valaciclovir (HSV-1/-2, VZV,
EBV, CMV), vidarabine (HSV-1/-2, VZV), brivudine (HSV-1, VZV), foscarnet (HSV-1/-2, CMV),
lamivudine (HBV, HIV-1/-2), peginterferon α-2a (HBV, HCV), peginterferon α-2b (HBV, HCV),
ribavirine (RSV, HCV), tenofovir disoproxil (HBV, HIV-1/-2), and trifluridine (HSV-1/-2, VACV)
can target more than one VD [4]. Considering this, there is an urgent need for the development of
novel antivirals, including drugs against emerging and re-emerging VDs.
Apoptosis is a cellular antiviral process that can be exploited in development of such drugs [5,6].
During this process, pattern recognition receptors (PRRs) recognize the invading viruses and signal to
Bcl-2 proteins [7]. The anti-apoptotic (Bcl-2, Bcl-xL, and Bcl-w) and pro-apoptotic (Bax, Bak, and Bad)
Bcl-2 proteins associate or dissociate with each other using Bcl-2-homology 3 (BH3) domains to start a
cascade of events, which leads to mitochondria membrane permeabilization (MoMP), cytochrome c
release, and eventually cell death [8–11].
Anti-apoptotic Bcl-2 proteins may represent cellular targets for novel antivirals [12–14]. Moreover,
commercially available Bcl-2 inhibitors (Bcl-2i) could be tested as antivirals. In particular, the antiviral
properties of two structurally distinct classes of anticancer agents could be investigated. The first
class includes ABT-737 and its derivatives ABT-263 and ABT-199, whereas the second class includes
WEHI-539 and its derivatives, A-1331852 and A-1155463 [15–21]. Interestingly, ABT-263 is currently
in clinical trials, and ABT-199 is approved to treat multiple lymphoid malignancies. However, only
A-1155463 causes reversible thrombocytopenia in animals [22,23].
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Here, we showed that ABT-263 limited the replication of IAV, FLUBV, Middle East respiratory
syndrome coronavirus (MERS-CoV), Zika virus (ZIKV), HBV, HSV-1 and -2, and echovirus 1 and 6
(EV1 and EV6) by inducing the premature death of virus-infected cells at concentrations not toxic for
non-infected cells. We further showed that ABT-263 induced apoptosis in cells transfected with viral
RNA or plasmid DNA but not in mock-transfected cells, suggesting that this compound accelerated
apoptosis in response to foreign nucleic acids. We also demonstrated that ABT-737, ABT-199,
WEHI-539, A-1331852, and A-1155463 can specifically induce the premature death of IAV-infected
cells, but only ABT-737, ABT-263, A-1331852, and A-1155463 limited viral replication. A comparison
of the toxicity, antiviral activity, and side effects of these Bc2i allowed us to select A-1155463 as an
antiviral lead candidate. Thus, we discovered a potential solution for the prevention and treatment of
a broad-spectrum of VDs.
2. Materials and Methods
2.1. Reagents
ABT-199, ABT-263, ABT-737, WEHI-539, A-1331852, A-1155463, obatoclax, and gemcitabine were
purchased from Selleck Chemicals (Houston, TX, USA), Saliphenylhalamide (SaliPhe) was synthesized
as described previously [24]. 10 mM solutions of the compounds were prepared in 100% dimethyl
sulfoxide (Sigma-Aldrich, St. Louis, MO, USA) and stored at −80 ◦C. Lyophilized lipopolysaccharide
(LPS, 10 mg/mL) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Plasmid pEGFP was from
Clontech (Mountain View, CA, USA) (cat #: HLP309). Hoechst 33342 (20 mM solution; cat #: 62249)
and ATP (10 mM solution; cat #: PV3227) were from Thermo Fisher Scientific (Waltham, MA, USA).
Genomic RNA was isolated from influenza A/WSN/1933 strain as described previously [11].
2.2. Viruses
Human influenza A/Udorn/307/1972 (H3N2) and B/Shandong/7/97 viruses were grown in
embryonated hen eggs as described previously [25,26]. EV1 and EV6 strains were propagated in
a monolayer of african green monkey kidney (Vero) and adenocarcinomic human alveolar basal
epithelial A549 cells, respectively, as described earlier [27,28]. Vero cells were used to prepare HSV-1
and -2 stocks as described previously [29]. ZIKV FB-GWUH-2016 strain was cultured in Vero E6 cells
as described earlier [30]. Semliki Forest virus (SFV) expressing VA7-mCherry was generated by the
in vitro transcription of pSP6-SFV4 cDNA and the electroporation of mRNA in baby hamster kidney
(BHK) 21 cells as previously described [31]. HBV particles were prepared from the culture supernatant
of HepAD38 cells as described previously [32]. MERS-CoV was propagated in a monolayer of Vero
cells for three days at 37 ◦C as previously described [33]. The virus stocks were stored at −80 ◦C.
All the experiments with viruses were performed in compliance with the guidelines of the national
authorities using appropriate Biosafety laboratories under appropriate ethical and safety approvals.
2.3. Cells
All cells were propagated at 37 ◦C in 5% CO2. Human retinal pigment epithelial (RPE) cells
were grown in Dulbecco's modified Eagle's medium (DMEM) F12 supplemented with 50 U/mL
penicillin-streptomycin (PenStrep), 2mM L-glutamine, 10% fetal bovine serum (FBS), and 0.25%
sodium bicarbonate (Sigma-Aldrich). Virus growth medium (VGM) for RPE contained 0.2% BSA,
2 mM L-glutamine, 0.348% NaHCO3, and 1 µg/mL l-1-tosylamido-2-phenylethyl chloromethyl
ketone-trypsin (TPCK)-trypsin (Sigma-Aldrich) in DMEM-F12. Human A549 cells were grown in
DMEM medium, supplemented with 50 U/mL PenStrep, 2 mM L-glutamine, and 10% FBS. VGM for
A549 contained 0.2% BSA, 2 mM L-glutamine, and 1 µg/mL 1-tosylamido-2-phenylethyl chloromethyl
ketone-trypsin (TPCK)-trypsin (Sigma-Aldrich) in DMEM. Pa02C were grown in regular DMEM
supplemented with 10% FBS. HepG2-NTCP2 cells were maintained in DMEM supplemented with 10%
FBS, 2 mM L-glutamine, 50 U/mL penicillin, and 50 µg/mL streptomycin as previously described [32].
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Vero cells were grown in high glucose DMEM supplemented with 10% heat-inactivated FBS and
1× Antibiotic-Antimycotic solution (Gibco/Life Technologies, Carlsbad, CA, USA).
2.4. Compound Toxicity and Efficacy Assays
Approximately 4 × 104 cells were seeded in each well of a 96-well plate. The cells were grown
for 24 h in appropriate cell growth medium. The media was replaced with VGM containing CellTox
Green Express cytotoxicity reagent (CTxG, 1:2000 dilution in the assay well, Promega, Madison, WI,
USA). The compounds were added to the cells in three-fold dilutions at seven different concentrations
starting from 10 µM. No compounds were added to the control wells. The cells were mock- or
virus- infected. The multiplicity of infection (moi) was 0.1 to 3 depending on the virus strain. When
Bcl-2i induced a cytopathic effect in virus-infected cells (typically on 12–24 h), the cells were imaged
using a Cytation 5 Imaging reader (BioTek Instruments Inc., Winooski, VT, USA) in a bright-field
or fluorescent mode (485–500 nmEx/520–530 nmEm) and the fluorescence was measured with a
PHERAstar FS plate reader (BMG Labtech, Ortenberg, Germany). The media was removed from
the cells. CellTiter-Glo viability (CTG, Promega, Madison, WI, USA) reagent was added (30 µL
per well). The luminescence was measured with a PHERAstar FS plate reader. The raw data was
normalized against calibration (standard) curves. The curves were generated using purified human
genomic DNA or ATP (Sigma Aldrich). Each of the curves was fitted using logistic regression analysis,
with R2PRESS = 0.997 and R2PRESS = 0.995 for the dsDNA and ATP calibration curves, where R2PRESS is
a predicted coefficient of determination R-squared calculated from the predicted residual error sum of
squares (PRESS) statistic [34]. This allowed accurate estimation of unknown concentrations by finding
intersects with known fluorescence and luminescence measurements on the calibration curve.
2.5. Scoring Drug Response Profiles
The dose-response curves were fitted with four-parameter logistic functions (Equation (1)), where
Amin and Amax are the upper and lower asymptotes (minimal and maximal drug effects), m is the dose
that produces the half-maximal effect, and λ is the steepness (slope) of the curve.
f (x) = Amin +
Amax − Amin
1 +
( x
m
)λ (1)
We used a composite trapezoidal rule to estimate the area under the dose-response curve
(AUC), which is a commonly used metric for the quantification of drug responses through multiple
dose-levels [35–37]. This allowed us to calculate differential AUC (dAUC) between two dose-response
curves (for example, plus minus virus).
The half maximal cytotoxic concentration (CC50), the half maximal effective concentration (EC50)
for each compound was determined as described previously [38]. The relative effectiveness of the drug
was defined as the therapeutic or selectivity index (SI = CC50/EC50).
2.6. Virus Titration
The cells were treated with 1 µM Bcl-2i or remained non-treated and infected with a virus. After
24 h, supernatants were collected, serially diluted in PBS, and added to Vero-E6, MDCK, or A549
cells. The media was changed, and the cells were overlaid with plaque assay media. The cells were
fixed, and viral titers were calculated. The titers were expressed as plaque-forming units (PFU), 50%
tissue culture infective dose (TCID50), or fluorescence-forming units (FFU)/mL. The EC50 values as
well as the ratios between virus titers in non-treated and compound-treated cells at certain Bcl-2i
concentrations were calculated.
IAV and FLUBV were titered using plaque assay on MDCK cells, as described earlier [25]. EV1
and EV6 titers were also determined by plaque assay on A549 cells [39]. HSV-1 and HSV-2 titers were
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determined by plaque titration in Vero cells in the presence of human immunoglobulin G (20 µg/mL) as
described earlier [29]. SFV4 was titered by plaque assay on BHK-21 cells, as previously described [31].
2.7. Transfections of RPE Cells with vRNA or Plasmid DNA
RPE cells were cultured to 80% confluence in 96 well plates and transfected with 160 ng viral
genomic RNA using Lipofectamine RNAiMAX (Thermo Fisher Scientific, Waltham, MA, USA) or
with 30, 100, or 300 ng of plasmid DNA (pEGFP) using Lipofectamine 3000 (Thermo Fisher Scientific,
Waltham, MA, USA).
2.8. Live Microscopy of Semliki Forest Virus Infection During Bcl-2-Inhibition
One thousand Pa02C cells were seeded per well in 384-well plates in duplicate in the presence
of 1:2000 dilution of CellToxGreen reagent. Cells were infected with 10 PFUs per well of SFV vector
VA7-mCherry [31]. Plates were placed in an Incucyte Zoom live microscope (Essen Bioscience,
Ann Arbor, MI, USA) and set to image every 30 min. Movies were assembled using all frames,
while still images show the cells every 2 h.
2.9. Dynamic BH3 Peptide Profiling
Dynamic BH3 profiling was performed as described previously [40]. Briefly, 4 × 104 RPE cells
were plated per well in 96-well plates (Corning, Corning, NY, USA). After 16 h, the cells were infected
with IAV or transfected with pEGFP plasmid using Lipofectamine 3000 following the manufacturer’s
instructions. Three hours post infection and one hour post transfection, the medium was replaced with
100 µL of Derived from Trehalose Experimental Buffer (DTEB). The DTEB contained 135 mM trehalose,
50 mM KCl, 20 µM EDTA, 20 µM EGTA, 0.1% BSA, 5 mM succinate, 10 mM HEPES-KOH, 0.005%
digitonin, 10 µg/mL Oligomycin A, 5 µM β-mercaptoethanol, 1 µM JC-1 fluorescent probe (all from
Sigma), and BH3-domain peptides BIM (1 µM), BID (5 µM), PUMA (5 µM), NOXAA (5 µM), BAD
(10 µM), HRK (5 µM; KJ Ross-Peterssen, ApS, Copenhagen, Denmark), or DMSO (Sigma-Aldrich).
The fluorescent signal was measured at λ = 593 nm for 150 min with 10 min intervals using a Cytation
5 Imaging reader (BioTek Instruments Inc., Winooski, VT, USA). The kinetic curves were plotted
and analyzed using GraphPad Prism7 (GraphPad Software Inc., La Jolla, CA, USA). Mitochondrial
depolarization and delta apoptotic priming were calculated as described [40].
2.10. Metabolomics
Metabolomics analysis was performed as described previously [41]. Briefly, 10 µL of labeled
internal standard mixture was added to 100 µL of the sample (cell culture media), and 0.4 mL of
solvent (99% ACN and 1% FA) was added to each sample. The samples were filtered. Sample analysis
was performed on an Acquity UPLC-MS/MS system (Waters Corporation, Milford, MA, USA). The
detection system, a Xevo TQ-S tandem triple quadrupole mass spectrometer (Waters, Milford, MA,
USA), was operated in both positive and negative polarities with a polarity switching time of 20 msec.
Electro spray ionization was chosen as the ionization mode with a capillary voltage at 0.6 kV in both
polarities. The source temperature and desolvation temperature of 120 ◦C and 650 ◦C, respectively,
were maintained constantly throughout the experiment. The declustering potential and collision
energy were optimized for each compound. The Multiple Reaction Monitoring (MRM) acquisition
mode was selected for the quantification of the metabolites with an individual span time of 0.1 s
given in their individual MRM channels. The dwell time was calculated automatically by the software
based on the region of the retention time window, the number of MRM functions, and also depending
on the number of data points required to form the peak. MassLynx software (version 4.1, Waters
Corporation, Milford, MA, USA) was used for data acquisition, data handling, and instrument control.
Data processing was done using TargetLynx software (Waters Corporation, Milford, MA, USA), and the
metabolites were quantified by calculating the curve area ratio using labeled internal standards and
external calibration curves. The metabolomics data was log2 transformed for linear modeling and
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empirical-Bayes-moderated t-tests using the R/Bioconductor software package limma [42]. To analyse
the differences in metabolites levels, a linear model was fit to each metabolite. The Benjamini-Hochberg
method was used to correct for multiple testing. The significant metabolites were determined at a
Benjamini-Hochberg false discovery rate (FDR) controlled at 10%. The heatmap was generated
using the pheatmap package based on log transformed profiling data. MetaboAnalyst (version 3.0,
McGill University, Ste. Ann de Bellevue, QC, Canada) was used to identify the metabolic pathways
associated with virus infection or affected by Bcl-2i treatment [43].
2.11. Immuno-Precipitation and Mass-Spectrometry
The Bcl-xL-, Bcl-2-, or Mcl-1-associated factors were immuno-precipitated from IAV-infected and
non-infected RPE cells using rabbit anti-Bcl-xL, Bcl-2, or Mcl-1 antibodies (1:200; Cell Signalling
Technology, Danvers, MA, USA), separated with sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and visualized by Coomassie staining. The entire lanes or specific protein
bands were cut. The proteins were in-gel digested with trypsin. The resulting peptides were analyzed
using liquid chromatography–tandem mass spectrometry, as described previously [11,44]. The mass
spectrometry data were searched using in-house Mascot and the ProteinPilot interface against the
SwissProt database. Only statistically significant data (p < 0.05) were selected.
3. Results
Our dynamic BH3 peptide profiling revealed that Bad, Bim, Bid, Puma, and Noxa enhanced
MoMP in IAV- but not in mock-infected human non-malignant RPE cells, which represent natural
targets for IAV infection (Figure S1) [45–50]. A co-immunoprecipitation experiment using antibodies
against pro-survival Bcl-xL, Bcl-2, or Mcl-1 followed by mass spectrometry showed that several cellular
proteins, including Bad, Bax, Bak, UACA, PAWR, FLII, Trim21, IMMT, 14-3-3, EFHD2, DHX9, DDX3,
NLRP3, and LRRFIP2, as well as viral factors M1, NS1, HA, and NP were present in the complexes
(Figure S2). Thus, these experiments demonstrated that pro-apoptotic Bcl-2 proteins (Bad, Bax, Bak),
PRRs (DHX9, DDX3, LRRFIP2), and other factors can be involved in the programmed death of
IAV-infected cells.
It was shown that ABT-263 targets Bcl-xL and Bcl-2 and alters their interaction with pro-apoptotic
Bax, Bad, and Bak [19,20]. We tested the effect of ABT-263 on the viability of RPE cells infected with
IAV or mock by carrying out dose response studies. As readouts, we used fluorescent microscopy,
which visualizes dead (green) and living (blue) cells. Fluorescent microscopy revealed that ABT-263
induced the premature death of IAV-infected cells at concentrations not toxic for non-infected cells
(Figure 1A).
We validated the results with the CTxG and CTG assays. The CTxG assay uses fluorescent
asymmetric cyanine dye that stains the DNA of dead cells, whereas CTG assay quantifies ATP,
an indicator of metabolically active living cells. We calculated the values of the differential area under
the dose-response curves between the mock- and IAV-infected cells for both assays (∆AUCCTG and
∆AUCCTG; Figure 1B,C,E). High values indicate that ABT-263 was an effective trigger of the premature
death of infected cells. In infected cells, the effect was observed already at 12 h post infection, whereas
no toxicity was detected for at least 36 h at 0.4 µM ABT-263 in the mock-infected cells (Figure 1E).
Moreover, the effect was dependent not only on the dose of ABT-263 but also on the viral load
(Figure 1D).
In addition, we evaluated the effect of ABT-263 on IAV replication by tittering viruses produced
in cells treated and non-treated with ABT-263. ABT-263 treatment lowered IAV production in RPE
cells, as indicated by the fold change between virus titers (Figure 1D,E). We obtained similar results in
A549 cells (Figure S3). Furthermore, ABT-263 activated caspase 3 in IAV-infected but not in non-treated
or ABT-263-treated mock-infected RPE cells at 12 h post infection (Figure S4). These results collectively
suggest that ABT-263 induced premature apoptosis in IAV-infected cells and lowered IAV production.
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Figure 1. At 24 h post infection, ABT-263 kills influenza A (IAV)-infected but not mock-infected RPE 
cells and lowers the production of infectious viral particles. (A) Fluorescent microscopy images 
showing that increasing concentrations of ABT-263 kill IAV-infected (moi 3) but not mock-infected 
retinal pigment epithelium (RPE) cells at 24 h. Asymmetric cyanine dye stains the dsDNA of dead 
cells. Hoechst stains DNA in living cells; (B) quantification of dsDNA in dead cells using 
CellToxGreen cytotoxicity (CTxG) assay. Mean ± standard deviation (SD), n = 3; (C) quantification of 
intracellular ATP in living cells using CellTiter-Glo luminescent cell viability (CTG) assay. Mean ± 
standard deviation (SD), n = 3; (D) RPE cells were non- or ABT-263-treated (0.4 μM) and infected with 
IAV at moi 0.08, 0.4, 2, and 10. Cell viability was measured using a CTG assay 24 h after infection. 
Mean ± SD, n = 3; (E) RPE cells were non- or ABT-263-treated (0.4 μM) and mock- or IAV-infected 
(moi 3), and cell viability was measured using a CTG assay at the indicated time points. Mean ± SD, 
n = 3; (F) example of plaque assay measuring virus production in Bcl-2i- (3 μM) and DMSO-treated 
RPE cells at 24 hpi; (G) table summarizing the differential effect of ABT-263 on the viability of virus- 
and mock-infected cells, expressed as ΔAUCCxTG and ΔAUCCTG. It also shows the effect of ABT-263 on 
virus production in drug- (3 μM) and DMSO-treated RPE cells, which is expressed in log10 fold change 
(FC). Mean ± SD, n = 3. 
Figure 1. t 24 h post infection, ABT-263 kills influenza (IAV)-infected but not mock-infected
RPE cells and lowers the production of infectious viral particles. (A) Fluorescent microscopy images
showing that increasing concentrations of BT-263 kill I -infected ( oi 3) but not ock-infected
retinal pigment epitheliu ( PE) cells at 24 h. sy etric cyanine dye stains the dsDNA of dead
cells. Hoechst stains DNA in living cells; (B) quantification of dsDNA in dead cells using CellToxGreen
cytotoxicity (CTxG) assay. Mean ± standard deviation (SD), n = 3; (C) quantification of intracellular
ATP in living cells using CellTiter-Glo luminescent cell viability (CTG) assay. Mean ± standard
deviation (SD), n = 3; (D) RPE cells were non- or ABT-263-treated (0.4 µM) and infected with IAV at
moi 0.08, 0.4, 2, and 10. Cell viability was measured using a CTG assay 24 h after infection. Mean ± SD,
n = 3; (E) RPE cells were non- or ABT-263-treated (0.4 µM) and mock- or IAV-infected (moi 3), and cell
viability was measured using a CTG assay at the indicated time points. Mean ± SD, n = 3; (F) example
of plaque assay measuring virus production in Bcl-2i- (3 µM) and DMSO-treated RPE cells at 24 hpi;
(G) table summarizing the differential effect of ABT-263 on the viability of virus- and mock-infected
cells, expressed as ∆AUCCxTG and ∆AUCCTG. It also shows the effect of ABT-263 on virus production
in drug- (3 µM) and DMSO-treated RPE cells, which is expressed in log10 fold change (FC). Mean ± SD,
n = 3.
Importantly, ABT-263 induced the premature death of RPE cells infected with FLUBV, SFV,
or HSV-1 and lowered virus production, all at concentrations that are not toxic to non-infected cells
(Figure 2). We obtained similar results with ZIKV, EV1, EV6, MERS-CoV, HBV, and HSV-2 viruses using
different cell lines (Figure S5). Supplementary movies 1 and 2 further reaffirm that the treatment of
pancreatic cancer cells infected with SFV with ABT-263 at low moi attenuated the replication and spread
of the virus in these cells. These results suggest that Bcl-2i might be used as broad-spectrum antivirals.
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Figure 2. ABT-263 induces the premature death of cells infected with different viruses. (A) CTxG
and (B) CTG plots showing the ABT-263 induces the premature death of RPE cells infected with
FLUBV, SFV4, or HSV-1 viruses (moi 1) but not those infected with mock. Mean ± SD, n = 3; (C) table
summarizing the differential effect of Bcl-2i on the viability of virus- and mock-infected cells, expressed
as ∆AUCCxTG and ∆AUCCTG. It also shows the effect of ABT-263 on virus production in drug- (3 µM)
and DMSO-treated RPE cells, which is expressed in log10 fold change (FC).
We hypothesized that viral or any oth r foreign RNA or DNA could trigger ABT-263-sensitized
apoptosis. To test this, we transfected RPE cells with IAV RNA (vRNA) or plasmid DNA (pDNA) and
treated transf cted cells with ABT-263. Viral RNA- or pDNA, but not mock-transfected cells, rapidly
died after ABT-263 treatment (Figure 3 and Figur S6 A,B). It s important to not that cell death was
d pendent on the amount of transfected vRNA and pDNA, as well as on concentration of ABT-263.
Moreover, BH3 peptides of Puma, Bad, and Bid induc d MoMP in pDNA-tr nsfected ABT-263-tr ated
cells as early as 3 h post transfection, in contrast to cells treated with ABT-263 or cells transfected with
pDNA (Figure S6 F). As expected, ABT-263 did not accelerate the death of RPE or A549 cells treat
with bacterial lipopolysaccharides (LPS), which are recognized by different PRRs to those that detect
intracellular foreign RNA or DNA (Figure S6C–E).
In th next experimen , we pre-treated RPE or A549 cells with co unds hat inhibi the
endocytic uptake (obatoclax or SaliPhe) or the transcription and replication f IAV (JNJ-872 r
gemcitabin) [46,51] and infect d them with IAV. ABT-263 did not show any effect on these
cells (Figure S7). These re ults confirmed that intra ellul r foreign RNA/DNA or its replication
intermediates riggered apoptosis, and Bcl-2i acc lerate this process.
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Figure 3. ABT-263 induces the premature death of cells transfected with IAV genomic RNA
(vRNA) or plasmid DNA (pDNA). (A) Fluorescent microscopy images showing that ABT-263 kills
vRNA-transfected (160 ng) but not mock-transfected RPE cells at 8 h post transfection. Asymmetric
cyanine dye stains the dsDNA of dead cells. Hoechst stains DNA in living cells; (B) CTxG plot
showing that ABT-263 (3 µM) induces that premature death of RPE cells transfected with increasing
concentrations of vRNA. Mean ± SD, n = 3; (C) Fluorescent and bright field microscopy of RPE cells
showing that ABT-263 kills eGFP-expressing plasmid transfected (300 ng) but not mock-transfected
RPE cells at 6 h post transfection; (D) CTG graph showing that the viability of ABT-263-treated (3 µM)
cells decreases with increasing concentrations of transfected plasmid DNA. Mean ± SD, n = 3.
In order to provide further clues on the mechanisms of Bcl-2i-sensitized apoptosis, we investigated
the effect of ABT-263 analogues (ABT-737, ABT-199, WEHI-539, A-1331852, and A-1155463) on the
viability and death of IAV-infected and mock-infected RPE cells at 24 hpi (Figure 4). In addition,
we evaluated the effect of these compounds on IAV replication by titering the viruses produced in
cells treated with increasing compound concentrations. We calculated CC50, EC50, and SI values for
each compound. We observed that ABT-263 was more selective than structurally similar ABT-737 and
ABT-199, whereas A-1155463 was more selective tha structurally similar A-1331852 and WEHI-539
(Figures 4 a d 5A). Importantly, th treatm nt of non-infected RPE c lls with these compounds altered
the levels of secreted denine, adeno i e, hypoxa thine, IMP, AMP, inosine, n xanthosine, which
belong to th ATP etabolic pathway (Figure S8). Altogether, these results suggest hat A-1155463
may represe t an antiviral lead candidate.
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IAV-infected (moi 3) but not mock-infected RPE cells at 24 hpi. Asymmetric cyanine dye stains the 
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Figure 4. Anti-IAV activities of ABT-263 analogues. (A,B) Structures of ABT-263, ABT-737, and ABT-199,
as well as WEHI-539, A-1331852, and A-1155463, showing that these molecules share similar elements;
(C) fluorescent microscopy images showing that increasing concentrations of Bcl-2i kill IAV-infected
(moi 3) but not mock-infected RPE cells at 24 hpi. Asymmetric cyanine dye stains the dsDNA of dead
cells. Hoechst stains DNA in living cells; (D) quantification of dsDNA in dead cells. Mean ± SD, n = 3;
(E) quantification of intracellular ATP in living cells using CTG assay. Mean ± SD, n = 3.
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4. Discussion
Generally, antivirals interfere with virus replication to prevent cell death. This can be achieved by
the inhibition of critical steps of the virus replication cycle either by direct virus targeting or by targeting
a host cell function. Here, we described an alternative approach, in which small molecules limited
virus replication and spread by inducing the death of infected cells without affecting non-infected cells.
We showed that ABT-263 induced the premature apoptosis of IAV-infected cells at physiologically
relevant concentrations. ABT-263 also facilitated apoptosis in cells infected with FLUBV, SFV, ZIKV,
EV1, EV6, MERS-CoV, HBV, HSV-1, and HSV-2 or transfected with IAV vRNA or plasmid DNA. We
concluded that foreign RNA/DNA triggered apoptosis in ABT-263-sensitized cells. It should be noted
that other factors (such as IAV M2, PB1-F2, NS1, HA, and NP proteins, or HSV ICP27, ICP4, ICP10
PK, Us3, gD, and gJ) may further accelerate or decelerate apoptosis by disrupting or stabilizing the
interactions of cellular BH3-domain proteins in infected cells [11,52–55].
Furthermore, we demonstrated that ABT-263-sensitized apoptosis was dependent on the load
of viral nucleic acids. In particular, ABT-263 treatment induced apoptosis during the early stages of
a viral infection if the viral load as high or during the late stages of a viral infection if the initial
concentration of viral nucleic acid as lo . In both cases, BT-263 treat ent could prematurely
terminate viral replication. Mechanistically, P Rs recognized intracellular viral RNA/DNA and
sent signals to anti-apoptotic Bcl-2 proteins. Bcl-2 proteins released their pro-apoptotic part ers to
initiate MoM , ATP degradation and caspase-3 activation. This resulted in cell death. ABT-263 acted
synergistically with viral RNA/ , t r , f ilit t ll t ( i re 5B).
We also demonstrated that ABT-737, ABT-199, WEHI-539, A-1331852, and A-1155463 specifically
induced the premature death of IAV-infected cells, bu only ABT-737, ABT-263, A-1331852, and
A-1155463 limited viral replica ion. Importantly, ABT-263 was more effective than st ucturally similar
ABT-737 nd ABT-199, whereas A-1155463 was more effective than structurally s milar WEHI-539 and
A-1331852. A-1155463, unlike ABT-263, causes reversible thrombocytopenia, which made it a suitable
antiviral lead candid te [22,23].
The str t f A- 1 5463 and its analogues bound to Bcl-xL may provid further ideas
for the development f this compound as an antiviral (Figure S9) [15,19,21–23]. The binding
of A-1 5 463, A-1331852, and WEHI-539 to their targets induces major onformational change
(7 Å backbone movement) in the Bcl-xL that disrupts the local (R103-D107) helical structure of
the protein. This structural change is not seen with ABT-263, ABT-737, and ABT-199 binding as
these compounds contain chlorophenyl moiety compared to A-115463, A-1331852, and WEHU-539
benzothiazole moiety. Moreover, A-1155463 has additional moiety, which perturbs the Bcl-xL structure
and may affect its binding with its anti-apoptotic partners (such as Bad, Bax, and Bak) and, perhaps,
other proteins (such as DHX9, LRRFIP2, PAWR, UACA, NS1, M1, NP, and HA). It is possible that,
not only the high affinity of A-1155463 to Bcl-xL protein, but also its capacity to alter protein-protein
interactions could be important for its pro-apoptotic antiviral effect.
Several critical issues should be also considered while developing A-1155463 or its derivatives as
antivirals. While A-1155463 may possess broad-spectrum antiviral activity in vitro and against some
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other viruses in primary patient samples ex vivo [12–14], its antiviral efficacy should be evaluated
in vivo. Also its side effects, including its immuno- and neuro-modulatory properties, should be
studied in detail. In particular, A-1155463 or its derivatives may possess adverse effects in acute virus
infection. The viral dose is likely to be high, infecting a large number of cells. Inducing apoptosis may
result in extensive tissue damage. Thus, A-1155463 or its derivatives must be evaluated as prophylactic
rather than as therapeutic agents against viruses that cause acute infections.
5. Conclusions
We can explore our knowledge in virus-host interaction to develop pharmacological interventions
to control viral infections. In particular, our understanding of virus-mediated cell death highlighted the
potential use of apoptosis-inducing molecules as antiviral drugs. Our study suggests that A-1155463
may be a lead pro-apoptotic compound with antiviral properties. The prophylactic use of A-1155463
and its derivatives might help to prevent severe viral diseases.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1999-4915/9/10/
271/s1.
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